CamMed Therapeutics closed pre-seed round with ZINC VC, SFC Capital and KQ Labs (Crick Institute).

Written By Ahmet Can Berkyurek

CamMed Therapeutics has successfully closed its pre-seed funding round, with backing from Zinc VC, SFC Capital, and KQ Labs at the Francis Crick Institute.

The funding will support key early-stage activities, including validation in human and mouse cells, benchmarking against circular RNA and other RNA technologies, and initial animal proof-of-concept studies. These milestones are expected to position the company for a future seed round.

The investment has also enabled the expansion of the team, with two new hires bringing strong expertise in RNA biology, therapeutics, and delivery. We are happy to welcome Dr. Virginia Castilla Llorente and Dr. Reeta Daswani to our team.

Ahmet Can Berkyurek
Next

We published our ideas and vision on Advancing RNA with Michael Solaway.